
Hiring
AI Proteins Announces The Appointment Of Dr. Robert Stein To Its Scientific Advisory Board
By Business Wire
.png?ext=.png)
Share


- Dr. Stein is an industry leader with over 35 years of experience in drug development -
BOSTON--(BUSINESS WIRE)--AI Proteins, Inc., a growing biotechnology company that utilizes computational de novo protein design to create novel therapeutic miniproteins, today announced the appointment of Robert Stein, MD, PhD, to its Scientific Advisory Board.
“The team and I at AI Proteins are ecstatic to welcome Dr. Robert Stein to our Scientific Advisory Board,” said Dr. Chris Bahl, founder, President, and Chief Scientific Officer of AI Proteins. “Bob is an icon in the pharmaceutical industry and a veteran drug hunter with a proven track record of success. He shares our vision for the promise of miniproteins as a next-generation modality with massive therapeutic opportunity. The incredible speed, efficiency, and capacity of our miniprotein platform have yielded a deep pipeline of assets that are poised to begin development. We are grateful to have the opportunity to work closely with Bob, and all of our SAB members, as we navigate this exciting and pivotal moment for AI Proteins.”
Dr. Robert Stein, an accomplished medical professional, has held various executive positions in research and development, contributing to the advancement and registration of several pharmaceuticals. Notably, he played a key role in the discovery and development of Sustiva®, Promacta®, and the blockbuster drug Eliquis®. With his expertise in molecular biology, biochemistry, and clinical development, Dr. Stein spearheaded the development of four checkpoint modulatory antibodies and a personalized neo-epitope-directed cancer vaccine. Dr. Stein currently is a Venture Partner at Samsara Biocapital. Additionally, he has held various leadership positions, including President of Roche Palo Alto LLC, Chief Executive Officer of Kinemed, and President of R&D at the immuno-oncology company Agenus. Dr. Stein holds an MD and a PhD in Physiology & Pharmacology from Duke University.
"AI Proteins’ compelling de novo protein design platform creates protein-based medicines that can effectively target multiple indications across a wide array of disease areas,” said Robert Stein, MD, PhD. “The rapidly evolving science of miniproteins has the potential to be substantially differentiated from current therapeutic modalities and help deliver better patient outcomes in indications with large unmet need. I look forward to supporting further advancement of this cutting-edge science and ideal therapeutic modality with AI Protein’s seasoned management and expert advisors who have strong protein engineering and drug development experience.”
“We are honored to have Dr. Stein join us at this important time for our Company,” said Noah D. Beerman, Chief Executive Officer of AI Proteins. “His appointment strengthens the already deep expertise present in our Scientific Advisory Board. Dr. Stein’s knowledge of drug development and commercialization will have an invaluable impact as AI Proteins enters our next phase of growth. We are excited to have an advisor of Dr. Stein’s caliber join our team and look forward to his insightful scientific and strategic guidance as we bring miniprotein therapeutics into development for indications with serious unmet medical need.”
In addition to Dr. Robert Stein, AI Protein’s current SAB members include Dr. Alice Bexon, Dr. Charlotte Deane, Dr. Todd Fehniger, Dr. Justin Gainor, Dr. Dennis Klinman, Dr. Carl Novina, Dr. Eric Rowinsky, and Dr. Omer Yilmaz.
About AI Proteins
Boston-based AI Proteins is a biotech company on a mission to re-imagine protein therapeutics with a novel approach for designing entirely new proteins. Using AI-based design and a high-throughput drug discovery platform, AI Proteins creates de novo proteins optimized for specific therapeutic applications. The AI Proteins platform enables the development of inexpensive, durable, highly specific proteins that have the potential for oral delivery. Additionally, the AI Proteins platform can dramatically accelerate the development of lead therapeutic candidates ready for IND-enabling studies. For more information, please visit aiproteins.com.
Contacts
Investor Contact:
Janhavi Mohite
Stern Investor Relations, Inc.
janhavi.mohite@sternir.com
+1 (212) 362-1200
First published on Wed, Oct 4, 2023
Liked what you read? That’s only the tip of the tech iceberg!
Explore our vast collection of tech articles including introductory guides, product reviews, trends and more, stay up to date with the latest news, relish thought-provoking interviews and the hottest AI blogs, and tickle your funny bone with hilarious tech memes!
Plus, get access to branded insights from industry-leading global brands through informative white papers, engaging case studies, in-depth reports, enlightening videos and exciting events and webinars.
Dive into TechDogs' treasure trove today and Know Your World of technology like never before!
Disclaimer - Reference to any specific product, software or entity does not constitute an endorsement or recommendation by TechDogs nor should any data or content published be relied upon. The views expressed by TechDogs' members and guests are their own and their appearance on our site does not imply an endorsement of them or any entity they represent. Views and opinions expressed by TechDogs' Authors are those of the Authors and do not necessarily reflect the view of TechDogs or any of its officials. While we aim to provide valuable and helpful information, some content on TechDogs' site may not have been thoroughly reviewed for every detail or aspect. We encourage users to verify any information independently where necessary.
Tags:
Related News on Hiring
Toss Securities Announces Appointment Of Gyubin Kim As New CEO
Thu, Oct 10, 2024
By PR Newswire
Modern Health Welcomes Adam Brown As Chief Financial Officer
Thu, Jan 16, 2025
By Business Wire
Comstock Metals Welcomes U.S. Senator Catherine Cortez Masto
Fri, Apr 26, 2024
By GlobeNewswire
JumpCloud Announces Micha Hershman As Chief Marketing Officer
Tue, Feb 6, 2024
By GlobeNewswire
IAS Appoints Industry Leader Bob Lord to its Board of Directors
Fri, Aug 2, 2024
By PR Newswire
PractiTest Welcomes Uri Tal Yosef As New Vice President Of R&D
Tue, Jul 25, 2023
By PR Newswire
Markel Appoints Richie Henry To Chief Operating Officer, Claims
Thu, Apr 6, 2023
By PR Newswire
Dremio Announces Sendur Sellakumar As Chief Executive Officer
Wed, Jul 5, 2023
By Business Wire
Avaya Bolsters C-Suite To Accelerate Business Transformation
Fri, Jun 16, 2023
By Business Wire
Wipro Appoints Soeren Lorenzen As Chief Growth Officer, APMEA
Thu, May 4, 2023
By Business Wire
illumifin Appoints Blake Bostwick as Chief Operating Officer
Thu, Mar 30, 2023
By Business Wire
Provenir Appoints Vincent Camara As Regional Leader In France
Thu, Mar 9, 2023
By Business Wire
GoCheck Kids Names Naveen Kathuria As Chief Executive Officer
Wed, Mar 8, 2023
By Business Wire
Kindred Announces Acquihire of Mango, Appoints Founder as CTO
Fri, Feb 3, 2023
By Business Wire
Myomo Appoints Yitzchak Jacobovitz to its Board of Directors
Tue, Jan 31, 2023
By Business Wire
Trending Business Wire
Uniswap Labs Introduces V4, The Most Flexible Defi Platform For Developers
By Business Wire
Alvaria And UJET Partner To Deliver A Secure And Compliant Cloud Contact Center Solution With Advanced Outbound Dialing Capabilities
By Business Wire
AI-Powered Analytics Platform, Unwrap, Secures Series A To Redefine Customer Intelligence
By Business Wire
Bigbear.Ai Awarded Prime IDIQ Contract For U.S. Department Of Navy's Seaport Next Generation (Nxg)
By Business Wire
Cyberark Helps Modernize Identity And Access Management For Linux Machines With New Identity Bridge Capability
By Business Wire
Join Our Newsletter
Get weekly news, engaging articles, and career tips-all free!
By subscribing to our newsletter, you're cool with our terms and conditions and agree to our Privacy Policy.
Join The Discussion